Ferdinando Riccardi

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo et al. · Journal of Clinical Oncology · 2012 · 234 citations · Full text

Medicine, Oncology, Pharmacology +16

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

Marcello Tiseo, Luca Boni, Francesca Ambrosio et al. · Journal of Clinical Oncology · 2017 · 184 citations

Medicine, Oncology, Pharmacotherapy +12

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

Maria Carmela Piccirillo, Paolo A. Ascierto, Carlo Salvarani et al. · Journal of Translational Medicine · 2020 · 112 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15

Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors

Francesco Panzuto, Maria Rinzivillo, Nicola Fazio et al. · The Oncologist · 2014 · 103 citations · Full text

Medicine, Oncology, Pharmacology +15